Oscar Health (OSCR) Q1 2026 earnings review
Massive Scale Delivers Historic Profits, But Risk Adjustment Danger Lurks
Oscar Health delivered a blowout first quarter for 2026, completely reversing the narrative of its troubled 2025. Revenue surged 53% YoY to $4.65B, driven by explosive membership growth (up 56% to 3.17M members) and aggressive 2026 rate increases. This top-line scale translated powerfully to the bottom line, generating $679M in net income and a record-low Medical Loss Ratio (MLR) of 70.5%. While management's aggressive pricing strategy appears fully vindicated in Q1, the underlying risk adjustment payable to CMS exploded to $4.7B. The company reaffirmed its FY26 guidance, projecting a highly profitable year, but investors must monitor whether the influx of healthy members triggers another mid-year risk adjustment true-up.
🐂 Bull Case
The ~28% average rate increases implemented for 2026 worked perfectly in Q1. The MLR compressed dramatically from 75.4% to 70.5%, proving Oscar can successfully reprice its book to cover elevated market morbidity.
With 3.17M members, Oscar is flexing massive scale. The SG&A ratio hit a record low of 15.2%, down 60 bps YoY, confirming that the technology stack and fixed-cost base can highly monetize new membership.
🐻 Bear Case
Oscar recorded a massive $1.37B current-year risk adjustment payable in Q1 alone. If CMS risk reports update adversely later this year—as they did in Q2 2025—it could wipe out these early gains.
Oscar absorbed massive market share due to competitor exits. However, high deductible plans and shifting premium economics mean a significant portion of these 3.17M members are at high risk of dropping coverage by Q3 or Q4.
⚖️ Verdict: 🟢
Bullish. Oscar is definitively reversing its 2025 losses. While the sheer size of the risk adjustment liability is unnerving, the 490 bps YoY improvement in MLR and strong SG&A leverage demonstrate core operational strength.
Key Themes
Aggressive Pricing Sparks Margin Renaissance
Oscar's strategy to execute ~28% rate hikes for 2026 paid off immediately. The Medical Loss Ratio (MLR) plummeted to 70.5% in 26Q1, down from 75.4% a year ago and a massive improvement from the 95.4% seen in 25Q4. Management attributes this reversing trend to a disciplined pricing strategy, favorable new member mix, and $68M in favorable prior period reserve development.
Explosive Market Share Capture
Membership reached a staggering 3.17 million in the Individual and Small Group segment, representing accelerating 57% YoY growth. This confirms Oscar successfully capitalized on competitors retreating from the ACA marketplace, turning an industry contraction into an aggressive market share grab.
Technology-Driven SG&A Leverage
The SG&A expense ratio decreased to 15.2% in 26Q1 from 15.8% in 25Q1. This accelerating operating leverage is driven by greater fixed cost absorption across the larger 3.17M member base, combined with disciplined cost management and AI-driven workflow efficiencies (like the Oswell and Agentic AI bots introduced in late 2025).
The Risk Adjustment Payable Monster
While the 70.5% MLR suggests pristine underwriting, the balance sheet tells a more concerning story. Net Risk Adjustment Payables exploded to $3.97B at the end of Q1, up from $1.87B a year ago. The company accrued $1.37B for the current year in Q1 alone. This contradicts the pure 'favorable margins' narrative: Oscar is onboarding exceptionally healthy, young members and will owe a massive chunk of premiums back to the ACA risk pool. If market morbidity forecasts are off, this payable will compress earnings in H2.
Favorable Development Masks Core Run-Rate
The 70.5% MLR benefited from $68 million of favorable prior-period reserve development in 26Q1. Without this one-time benefit, underlying medical costs would be slightly higher. While $68M is relatively small against $3.2B in direct medical expenses, relying on prior-period true-ups introduces earnings quality questions.
Looming Intra-Year Churn
Oscar's record Q1 membership historically represents the high-water mark for the year. In 2025, the company highlighted that members rolling off $0 premium plans due to higher deductibles creates severe mid-year churn. As the continuous Special Enrollment Period rules change, sustaining this 3.17M member base through Q4 will be highly improbable.
Macro: ACA Market Resilience Amidst Shifting Workforce
CEO Mark Bertolini highlighted macro tailwinds, stating, 'The workforce is shifting, the individual market is resilient, and Oscar is leading the transition to a consumer-driven health economy.' Despite fears of subsidy expirations and Medicaid redetermination fallout, the Q1 enrollment numbers validate the structural persistence of the individual ACA exchange market.
Product Shift: Launch of Lucie Health Marketplace
Oscar launched 'Lucie Health Marketplace,' a new all-in-one storefront designed to fundamentally change how consumers and brokers shop for healthcare. By offering every major individual market plan alongside supplemental products, Oscar is shifting from a pure health insurer to a broader healthcare distribution platform.
Other KPIs
A massive, accelerating increase from $878.5M in 25Q1. However, $1.99 billion of this cash flow was generated by the increase in 'Payables to CMS' (risk adjustment). Stripping out the CMS payable increase, core operating cash flow was roughly $625M. The balance sheet is flush with $4.8B in cash and equivalents, up from $2.77B at year-end.
Membership in the former Cigna+Oscar joint venture dropped to zero, confirming the complete wind-down of the small group partnership that had 17,983 members a year ago. Oscar's growth is now 100% organic direct-to-consumer and broker-led.
Guidance
Accelerating. Reaffirmed from prior quarters. The midpoint of $18.85B implies an explosive 61% YoY growth compared to FY25's ~$11.7B. Given the $4.65B generated in Q1, the company is firmly on track, assuming standard seasonal membership attrition.
Reversing. Reaffirmed guidance points to massive YoY improvement against FY25's 87.4%. While Q1 came in extraordinarily low at 70.5%, the full-year guide implies MLR will naturally drift higher into the mid-80s in the back half of the year as deductibles are met and seasonality kicks in.
Decelerating. Reaffirmed. Management expects a roughly 140 bps YoY improvement from FY25 (17.5%). Q1's 15.2% shows the company is currently operating ahead of its own efficiency targets, providing a strong cushion against membership churn later in the year.
Reversing. A massive swing from FY25's $396M operating loss. Interestingly, Q1 alone delivered $704M in Earnings from Operations. The fact that full-year guidance is much lower than the Q1 actuals indicates management expects significant operating losses in Q3 and Q4, underscoring the extreme seasonality and risk adjustment true-ups embedded in their model.
Key Questions
Risk Adjustment Cushion
You accrued an enormous $1.37B current-year risk adjustment payable in Q1. Given the volatility we saw in Wakely data during mid-2025, how conservative is this accrual, and what buffer do you have if market morbidity shifts against you again?
Seasonality of Earnings
You generated $704 million in Operating Earnings in Q1, but your full-year guidance is $250-$450 million. This implies an expected loss of roughly $350 million over the next three quarters. Is this purely driven by the 'barbell' risk adjustment dynamic and deductible seasonality, or are you forecasting severe membership attrition?
Lucie Health Marketplace Strategy
With the launch of Lucie, you are offering competitor plans alongside your own. How does this shift your economics from underwriting risk to distribution revenue, and what are your margin expectations for the Lucie platform standalone?
Bronze Plan Mix Dynamics
With the massive influx of 1.1 million new members, what is the current distribution between Bronze, Silver, and Gold? Are you seeing any early warning signs of anti-selection in the higher-tier metals?